Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

iShares Core S&P Small-Cap ETF

Vanguard Total Stock Mkt Idx Inv

Vanguard Tax-Managed Small Cap Adm

Sound Shore Investor

State St Russell Sm/Mid Cp® Indx NL Cl C

SPDR® S&P 600 Small Cap Value ETF

WEDGE QVM-Large Cap Value

Fidelity Extended Market Index

WisdomTree US SmallCap Dividend ETF

American Beacon Small Cp Val R5

Schwab US Small-Cap ETF™

Nordea Inv. PF PM Glb Aktier Fokus KL 1

Vanguard Small Cap Index

Vanguard Small Cap Value Index Inv

Vanguard Institutional Extnd Mkt Idx Tr

MFS Mid Cap Value Equity

MFS Mid Cap Value A

iShares S&P Small-Cap 600 Value ETF

SPDR® Portfolio S&P 600™ Sm Cap ETF

Nordea 1 - Global Stars Equity BI USD

BlackRock Inc

Vanguard Group Inc

Bank of New York Mellon Corp

Charles Schwab Investment Management Inc

Citadel Advisors Llc

Dimensional Fund Advisors, Inc.

Acadian Asset Management LLC

AQR Capital Management LLC

Slate Path Capital LP

Thompson, Siegel & Walmsley LLC

Private Management Group Inc

Kahn Brothers & CO Inc /DE/

Massachusetts Financial Services Company

State Street Corp

LSV Asset Management

Nordea Investment Mgmt Bank Demark A/s

Sound Shore Management Inc

Morgan Stanley - Brokerage Accounts

DePrince Race & Zollo Inc

Geode Capital Management, LLC

Organon & Co

Mr. Kevin  Ali

CEO & Director

Mr. Matthew M. Walsh C.F.A.

Executive VP & CFO

Mr. Kirke  Weaver

Executive VP, General Counsel & Corporate Secretary

Ms. Susanne Gabriele Fiedler

Executive VP & Chief Commercial Officer

Mr. Joseph T. Morrissey Jr.

Executive VP and Head of Manufacturing & Supply

Ms. Rachel A. Stahler

Executive VP & Chief Information Officer

Ms. Jennifer  Halchak

Head of Investor Relations

Ms. Susan  O'Neal

Chief Ethics & Compliance Officer

Ms. Rebecca Lowell Edwards

Chief Communications Officer

Mr. Daniel  Karp

Executive Vice President of Corporate Development

OGN's next earnings is on February 13, 2025 (Before Market Open)

OGN's latest dividend is 0.28 USD on August 16, 2024

Organon & Co (OGN) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Organon & Co (OGN) Earnings Report Date and History | NYSE

OGN's next earnings is on February 13, 2025 (Before Market Open)

When is the earnings report for OGN?

OGN Earnings History

OGN's latest dividend is 0.28 USD on August 16, 2024

OGN Stock Discussion Forum and Message Board

News for NYSE: OGN